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• How do we design more effective approaches for
paediatric CVA prevention in SCA?
• Could genetic variants act as modulators of CVA
severity and, if so, could they be used as
sensitive/specific biomarkers?
2. Research Question(s)
• Sickle cell anaemia (SCA) is an autosomal recessive
genetic disease, caused by a mutation in the HBB
gene, which results in the synthesis of an abnormal
haemoglobin (HbS)
• HbS polymerises inside red blood cells causing them
to be sickle-shaped, fragile, rigid and adherent-prone
to vessel walls (endothelium) and to other blood cells
• Several pathways also play a role in disease severity
such as endothelium dysfunction, cell adhesion, nitric
oxide metabolism and haemolysis (Fig.1)
• SCA most catastrophic complication: cerebral
vasculopathy (CVA), namely stroke and silent
cerebral infarcts (SCIs)
• Current therapeutic approaches for CVA:
• Transcranial Doppler, magnetic resonance
imaging (MRI) or computerized tomography (CT
scan) for risk assessment and diagnosis
• Hydroxyurea and chronic blood transfusions
• Primary CVA prevention and prognosis are still not
sensitive enough to detect all potentially affected
children nor to evaluate long term prognosis
1. Subject 3. Plan of Action
Genotyping/ 
Sequencing
Association 
Studies
Candidate genes
• VCAM1 (endothelial activation)
• ITGA4 (cell-endothelium adhesion)
• NOS3 (endothelial nitric oxide synthesis)
Sample selection
• 70 SCA children (>= 3 years old)
• Several degrees of CVA (stroke, SCI, 
risk, normal)
• Database with clinical, imaging and 
laboratory data
Statistic association
• Stroke, SCIs: ITGA4
• Stroke Risk: VCAM1
• Stroke or SCIs Protection: NOS3
• Haemolysis (markers): VCAM1, ITGA4
Gene 
Expression 
Studies
Pharmacological 
Studies
• Endothelial cell models
• Changes in gene expression levels / 
altered regulation of gene expression
• Endothelial cell models
• Drug targets
• Differential response to drug 
treatment
• Drug tests: hydroxyurea, glutamine
In Progress
Gene/Biomarker  
Panel
• Next generation sequencing panel
• Prognosis of disease severity
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Fig. 1. Sickle cell anemia pathophysiology
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